Edgewise Therapeutics reported a net loss of $40.7 million for the third quarter of 2025, or $0.39 per share, primarily due to increased research and development expenses. The company continues to advance its clinical programs for muscular dystrophies and cardiac conditions, with significant progress in its sevasemten, EDG-7500, and EDG-15400 programs.

Edgewise Therapeutics reported a net loss of $36.1 million for the second quarter of 2025, an improvement from the previous quarter's $40.8 million loss. The company's cash, cash equivalents, and marketable securities stood at approximately $594.0 million, indicating a strong financial position to advance its clinical programs.

Edgewise Therapeutics reported a net loss of $40.8 million for Q1 2025, with a slight increase in R&D expenses and stable G&A expenses. The company announced positive top-line results from its Phase 2 CIRRUS-HCM trial and completed a $200 million public offering, significantly strengthening its cash position.

Edgewise Therapeutics reported positive Phase 2 CANYON results, completed enrollment in GRAND CANYON, and advanced CIRRUS-HCM in Q4 2024. The company's cash, cash equivalents, and marketable securities were approximately $470.2 million as of December 31, 2024.

Edgewise Therapeutics reported strong progress on its cardiac and skeletal muscle programs, with key updates expected on the CIRRUS-HCM and CANYON Phase 2 programs in the coming months. As of September 30, 2024, the company's cash, cash equivalents, and marketable securities were approximately $492.5 million. The net loss for the quarter was $34.1 million, or $0.36 per share.

Edgewise Therapeutics reported second quarter 2024 financial results, highlighting progress in their cardiac and skeletal muscle programs. Key activities included completing the Phase 1 trial of EDG-7500 and advancing the Phase 2 CIRRUS-HCM trial. The company also continued to advance the GRAND CANYON global pivotal cohort and Phase 2 LYNX and FOX trials for sevasemten.

Edgewise Therapeutics reported positive two-year topline results from the ARCH open label trial and advanced the GRAND CANYON pivotal cohort in Becker. The company also initiated the Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with obstructive HCM.

Edgewise Therapeutics reported fourth-quarter financial results, with R&D expenses at $27.7 million and G&A expenses at $6.2 million. The net loss for the quarter was $30.1 million, or $0.47 per share. The company's cash, cash equivalents, and marketable securities totaled approximately $318.4 million as of December 31, 2023, excluding $231.8 million in net proceeds from a January 2024 underwritten offering.

Edgewise Therapeutics reported a net loss of $25.7 million for the third quarter of 2023. The company is advancing clinical trials for EDG-5506 and EDG-7500, including the initiation of the GRAND CANYON pivotal study in Becker muscular dystrophy and the FOX Phase 2 trial in Duchenne muscular dystrophy.

Edgewise Therapeutics reported cash, cash equivalents and marketable securities of $310 million as of June 30, 2023. Net loss for the second quarter of 2023 was $21.5 million, or $0.34 per share.

Edgewise Therapeutics started 2023 by advancing its LYNX and CANYON clinical trials of EDG-5506 and completing IND-enabling studies of EDG-7500. They plan to share 12-month ARCH open label data and interim Duchenne data from the Phase 2 LYNX trial and initiate a potentially registration-enabling cohort in CANYON and a Phase 1 trial for EDG-7500.

Edgewise Therapeutics reported a net loss of $19.4 million, or $0.31 per share, for the fourth quarter of 2022. The company's cash, cash equivalents and marketable securities were $352 million as of December 31, 2022. They are advancing EDG-5506 clinical trials and EDG-7500 IND-enabling studies.

Edgewise Therapeutics reported a net loss of $17.5 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $365 million as of September 30, 2022. They also completed an upsized underwritten public offering of common stock, resulting in net proceeds of $129 million.

Edgewise Therapeutics reported positive results from their EDG-5506 clinical trials in individuals with Becker muscular dystrophy, initiated Phase 2 trials in BMD, and anticipates starting Phase 2 trials in DMD in 2022. The company's cash, cash equivalents, and marketable securities totaled $248.4 million as of June 30, 2022.

Edgewise Therapeutics reported a net loss of $14.7 million, or $0.30 per share, for the first quarter of 2022. Cash, cash equivalents, and marketable securities totaled $265.8 million as of March 31, 2022. The company anticipates its cash resources will be sufficient to support planned growth and operations through 2024.

Edgewise Therapeutics reported positive topline results from the EDG-5506 Phase 1b clinical trial in adults with Becker muscular dystrophy (BMD). Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) are planned to start in 2022. Cash, cash equivalents and marketable securities were $281 million as of December 31, 2021.

Edgewise Therapeutics reported a net loss of $12.9 million for Q3 2021. The company's cash and marketable securities totaled $290 million as of September 30, 2021. They announced positive topline results from the EDG-5506 Phase 1 MAD study.

Edgewise Therapeutics reported cash, cash equivalents and marketable securities of $299 million as of June 30, 2021. Net loss for the second quarter of 2021 was $10.4 million, or $0.21 per share.

Edgewise Therapeutics reported financial results for the first quarter of 2021, highlighting a successful IPO that generated $202.4 million in gross proceeds and the advancement of EDG-5506 in clinical development. The company's cash and marketable securities reached $309.9 million as of March 31, 2021.